Amezcua-Guerra L, Santiago C, Espínola-Zavaleta N, Pineda C

Language: English
References: 13
Page: 39-43
PDF size: 52.72 Kb.

ABSTRACT

Patients with either Marfan syndrome or bicuspid aortic valve are at increased risk for aortic dilation and dissection, but occurrence of both conditions has barely been reported. Whether bicuspid aortic valve adversely impacts the cardiovascular outcome in Marfan syndrome patients is unknown. The objective was to investigate the prevalence of bicuspid aortic valve and to define whether its combined presence would adversely impact cardiovascular outcome in patients with Marfan syndrome. We performed a retrospective review on a Marfan syndrome database from a single center. Comparisons between patients with or without bicuspid aortic valve were performed by χ² or Student t test as appropriate. Bicuspid aortic valve was found in 4 of 89 Marfan syndrome patients (two males; mean age 21.5 ± 13 years) for 4.5% prevalence; in contrast, 1.5% prevalence was found in 200 control subjects (p = 0.1). Each patient with bicuspid aortic valve is separately discussed. Presence of bicuspid aortic valve shows trends for association with aortic dilation (Odds ratio [OR] 4.2; 95% Confidence interval [95%CI] 0.2-81), and aortic dissection (OR 5.5; 95%CI 0.7-42), while negative association with the Walker-Murdoch sign (OR 0.07; 95%CI 0.006-0.73) was found. Prevalence of bicuspid aortic valve in patients with Marfan syndrome patients is 4.5%. While it is intriguing and even intuitive that the concurrence of both conditions would lead to more aggressive aortic disease, a true synergistic role for aortic wall weakening cannot be supported.

REFERENCES

1. Januzzi JL, Isselbacher EM, Fattori R, et al. Characterizing the young patient with aortic dissection: results from the International Registry of Aortic Dissection (IRAD). J Am Coll Cardiol 2004; 43: 665-9.

2. Ince H, Nienaber CA. Etiology, pathogenesis and management of thoracic aortic aneurysm. Nat Clin Pract Cardiovasc Med 2007; 4: 418-27.

3. The Universal Mutation Database [updated 2007 July 20]. Available from: http://www.umd.necker.fr/disease.html.

4. Bonderman D, Gharehbaghi-Schnell E, Wollenek G, et al. Mechanisms underlying aortic dilatation in congenital aortic valve malformation. Circulation 1999; 99: 2138-43.

5. Nataatmadja M, West M, West J, et al. Abnormal extracellular matrix protein transport associated with increased apoptosis of vascular smooth muscle cells in Marfan syndrome and bicuspid aortic valve thoracic aortic aneurysm. Circulation 2003; 108(Suppl. II): II329-II334.

6. Fedak PWM, de Sa MPL, Verma S, et al. Vascular matrix remodeling in patients with bicuspid aortic valve malformations: implications for aortic dilatation. J Thorac Cardiovasc Surg 2003; 126: 797-806.

7. Gershoni-Baruch R, Moor EV, Enat R. Marfan syndrome associated with bicuspid aortic valve, premature aging, and primary hypogonadism. Am J Med Genet 1990; 37: 169-72.

8. Porciani MC, Attanasio M, Lepri V, et al. Prevalence of cardiovascular manifestations in Marfan syndrome. Ital Heart J Suppl 2004; 5: 647-52.

9. De Paepe A, Devereux RB, Dietz HC, Hennekam RC, Pyeritz RE. Revised diagnostic criteria for the Marfan syndrome. Am J Med Genet 1996; 62: 417-26.

10. Movahed MR, Hepner AD, Ahmadi-Kashani M. Echocardiographic prevalence of bicuspid aortic valve in the population. Heart Lung Circ 2006; 15: 297-9.

11. Faivre L, Collod-Beroud G, Loeys BL, et al. Effect of mutation type and location on clinical outcome in 1,013 probands with Marfan syndrome or related phenotypes and FBN1 mutations: an international study. Am J Hum Genet 2007; 81: 454-66.

12. Espínola-Zavaleta N, Casanova-Garcés JM, Muñoz-Castellanos L, et al. Echocardiometric evaluation of cardiovascular abnormalities in Marfan syndrome. Arch Cardiol Mex 2005; 75: 133-40.

13. Sariola H, Viljanen T, Luosto R. Histological pattern and changes in extracellular matrix in aortic dissections. J Clin Pathol 1986; 39: 1074-81.